Global Influenza Vaccines Market Outlook 2018-2028

Monday, August 6, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, August 6, 2018 /PRNewswire/ -- Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments for Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other

Read the full report: The latest report from business intelligence provider visiongain offers comprehensive analysis of the global influenza vaccines market. Visiongain assesses that this market will
generate revenues of $3.5 billion in 2018.How this report will benefit youRead on to discover how you can exploit the future business opportunities emerging in this sector. Visiongain's new study tells you and tells you NOW.In this brand new 138-page report you find 63 in-depth tables, charts and graphs -all unavailable elsewhere.The report provides clear detailed insight into the global Influenza market. Discover the key drivers and challenges affecting the market.By ordering and reading our brand new report today you stay better informed and ready to act.Report ScopeVisiongain's new investigation shows revenue predictions at overall world market, submarket, company, product and national level.That study gives individual analysis for two influenza vaccine submarkets, which are further divided by vaccine technologies:- Trivalent Influenza Vaccines (TIV)- Quadrivalent Influenza Vaccines (QIV)Our new analysis also shows you revenue predictions for the vaccines produced by these five market leaders: and their market share:- Sanofi Pasteur- GSK- Seqirus- AstraZeneca- Protein Science Corporation.- OthersFrom 2018, large pharmaceutical companies and other biopharma specialists can prosper in that market. See how, discovering organisations' potentials.Our report analyses the vaccines in research and development and assess their prospects once they enter the market. The R&D pipeline discusses:- Seasonal Influenza vaccines in development- Universal Influenza vaccines in developmentThe report includes forecasts to 2028 and analysis of pipeline developments for the following specific vaccines:- Fluzone / VaxiGrip- Seqirus- Fluarix / FluLaval- FluMist / Fluenz- FluBlok- OtherThe study shows you prospects for those drug sales in developed and developing regions. There see individual revenue forecasts to 2028 for 11 countries:- United States- Japan- The EU 5 -Germany, France, United Kingdom, Italy and Spain.- Brazil, Russia, India and ChinaWho should read this report?- Anyone within the influenza vaccines value chain.- Pharmaceutical companies- Vaccine manufacturers- Healthcare biotech companies- Generics and biosimilar producers- Drug delivery companies and other technology providers- Contract/clinical research organisations (CROs)- Pharma contract manufacturers,- Pharma/healthcare wholesale and distribution companies- Medical device companies- Healthcare diagnostics companies- R&D specialists- Business development managers- Marketing managers- Technologists- Suppliers- Investors- Banks- Government agencies- ContractorsRead the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:

SOURCE Reportlinker

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store